The Safety and Effectiveness of Megace in HIV-Infected Women
Completed
Bristol-Myers Squibb
Phase 4
1969-12-31
To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment
of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of
Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24
weeks.
Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite
Completed
National Cancer Institute (NCI)
Phase 3
2000-03-01
RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may
improve cancer-related weight loss and lack of appetite. It is not yet known whether
megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a
combination of both is most effective in treating cancer-related weight loss and loss of
appetite.
PURPOSE: Randomized phase III trial to compare the effectiveness of megestrol with or without
an omega-3 fatty acid-enriched nutritional supplement to that of the omega-3 fatty
acid-enriched nutritional supplement alone in treating patients who have cancer-related
weight loss and lack of appetite.
Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite
Completed
NCIC Clinical Trials Group
Phase 3
2000-03-01
RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may
improve cancer-related weight loss and lack of appetite. It is not yet known whether
megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a
combination of both is most effective in treating cancer-related weight loss and loss of
appetite.
PURPOSE: Randomized phase III trial to compare the effectiveness of megestrol with or without
an omega-3 fatty acid-enriched nutritional supplement to that of the omega-3 fatty
acid-enriched nutritional supplement alone in treating patients who have cancer-related
weight loss and lack of appetite.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
